QUOTE AND NEWS
The Hindu Business Line  Jun 14  Comment 
FMCG major Dabur India on Friday said it expects 20-25 per cent sales growth in the fruit juice segment this year on the back of new premium juices sub brand ’Super Fruits’ to be launched in the c...
The Hindu Business Line  Jun 10  Comment 
FMCG major Dabur India has expanded its skin care portfolio with the launch of gel-based facial bleach in the country. The company said the product — ‘Oxy Life Gel Bleach with Aloe Vera’,...
The Economic Times  Jun 4  Comment 
Buy Dabur India with a stop loss of Rs 158 and look for a price target of Rs 165.
The Hindu Business Line  May 27  Comment 
Dabur India has expanded its packaged food business by launching fruit juice-based drinking yoghurt under its Real Activ brand. Bollywood actress Bipash...
The Economic Times  May 27  Comment 
Dabur India Ltd is a ‘buy’ call with a target of Rs 160.50 and a stop loss of Rs 155.
The Economic Times  May 15  Comment 
On declines, Dabur can be bought into and this can entirely go into a different price zone.
The Economic Times  May 13  Comment 
"Dabur India Ltd is a 'BUY' call with a target of Rs 169 and a stop loss of Rs 160."
The Economic Times  May 9  Comment 
"NTPC, Dabur have performed well and will likely to continue to perform going ahead. "
The Economic Times  May 7  Comment 
"Dabur India Ltd is a ‘BUY’ call with a target of Rs 168 and a stop loss of Rs 157."
Mondo Visione  May 2  Comment 
Commences with listing of 3 companies — Dabur India Ltd. being the first company to list on the exchange Offers various benefits such as lower cost of issuance to issuers and zero processing fees and initial listing fee Exchange...
The Hindu Business Line  May 2  Comment 




RELATED WIKI ARTICLES

Related Articles

 

Dabur is India’s fourth largest FMCG company with interests in health care, personal care and food products. The company’s name is generic to ‘ayurvedic’ products in India and it has big brands like Vatika (hair oils), Chyawanprash, Hajmola, Amla oil and Lal Dant Manjan in its stable. In FY04, Dabur approved the demerger of its FMCG and pharma businesses into two separate listed entities. The move was aimed at bringing in more focus to both businesses, as well as to unlock value for shareholders. Further, the company acquired Balsara’s business in FY05 for a consideration of Rs 1.4 bn and Fem Care Pharma in June 2009 for Rs.2.5 bn.


Dabur reported an enticing topline growth of 19% YoY driven by growth in the consumer care division (up 15% YoY), foods (21% YoY) and its international business, which registered a strong 40% YoY growth for FY09. Operating profit for the company fell by 0.5% this fiscal due to higher raw material costs which was partially offset by cost cutting measures undertaken by the company. Bottomline continued to outpace topline growing by 32% YoY, which was possible due to savings from fiscal benefits from new manufacturing units and efficiencies. While the company has changed its product mix and revamped its portfolio along with judicious price increases, a sustained rise in raw material costs could hurt growth or margins or both.


Dabur’s broad product portfolio projects it as one of the best plays in the Indian FMCG space, not to forget its strong presence in less penetrated and high growth categories. Its ability to consistently launch new products and variants also gives it an edge. Further, its wide geographical reach is another strong advantage.


Consolidated Financials
Rs(m) 4QFY08 4QFY09 (%) Change FY08 FY09 (%) Change
Net sales 6,163 7,363 19.50% 23,850 28,310 18.70%
Expenditure 5,087 6,022 18.40% 19,517 23,351 19.60%
Operating profit (EBDITA) 1,076 1,341 24.70% 4,333 4,959 14.50%
EBDITA margin (%) 17.50% 18.20% 18.20% 17.50%
Other income 40 43 7.80% 100 213 112.10%
Interest 35 83 135.00% 168 232 38.20%
Depreciation 117 144 22.90% 421 492 17.00%
Profit before tax 964 1,157 20.10% 3,844 4,448 15.70%
Minority interest (29) (10) (66.00%) 1 4 215.40%
Tax 139 106 (23.90%) 516 540 4.70%
Profit after tax/(loss) 796 1,042 30.90% 3,329 3,911 17.50%
Net profit margin (%) 12.90% 14.20% 14.00% 13.80%
No. of shares (m) 864 865.1 864 865.1
Diluted earnings per share (Rs)* 4.5
Price to earnings ratio (x)* 23.4
* based on 12 month trailing earnings



Consolidated segment Revenue
4QFY08 4QFY09 (%) Change FY08 FY09 (%) Change
Consumer Care segment 4,636 5,568 20.10% 18,642 22,071 18.40%
% of total revenue 75.40% 75.50% 77.80% 77.90%
Consumer Health segment 582 677 16.30% 1,788 2,123 18.80%
% of total revenue 9.50% 9.20% 7.50% 7.50%
Food 757 929 22.80% 2,975 3,351 12.60%
% of total revenue 12.30% 12.60% 12.40% 11.80%
Retail Business 0 18 0 60
% of total revenue 0.00% 0.20% 0.00% 0.20%
Others 171 179 4.90% 558 736 31.90%
% of total revenue 2.80% 2.40% 2.30% 2.60%
Total 6,146 7,371 19.90% 23,962 28,341 18.30%



Division performance
Segment Growth Key performers
Hair oil 20.60% Dabur Amla (20.4%), Anmol Coconut (42.2%) , Vatika (12.2%), Anmol Mustard Oil (22.7%)
Shampoo 31.50% Vatika brands
Health Supplements 11.00% Chyawanprash (7.4% YoY), Glucose (21.6%) and Dabur Honey (12.6%)
Baby and Skin care 23.50% Gulabari (40.6%), Lal Tail (19.6%)
Oral care 5.00% Red toothpaste (21.4%), Meswak (17.2%)
Home care 10.00% Odonil (6.5%), Sanifresh (32.1%)
Foods 14.00% Real Fruit juice(14.9%), culinary range (19.6%)
Digestives 12.00% Hajmola tablets (13.7%), Hajmola Candy (17.9% )}


Quarterly Result Analysis- September '09

Performance summary

- Consolidated net sales for 2QFY10 and 1HFY10 increased by a robust 22% YoY each on the back of strong consumer spending coupled with new products rollout.

- Operating (EBITDA) margins improved by 2.2% to 21.2% for 2QFY10. This increase comes on the back of fall in raw material costs, offset to some extent by increase in advertisement costs as a percentage of sales. Operating margins for 1HFY10 increased by 1.7% to 19%. This increase comes on the back of slower growth in raw material costs as compared to sales, once again offset to some extent by a growth in advertisement expense by 47%

- Net profit margins for 2QFY10 increased by 0.9% to 16.3% while the same for 1HFY10 increased by 0.8% to 14.3%. The increase is on the back of higher sales and operating profits offset by increase in tax expenses.

Financial performance
(Rs m) 2QFY09 2QFY10 % Change 1HFY09 1HFY10 % Change
Net sales 6,993 8,540 22.10% 13104.5 16013 22.20%
Expenditure 5,664 6,726 18.80% 10832.1 12970 19.70%
Operating profit (EBDITA) 1,329 1,814 36.40% 2,272 3,043 33.90%
EBDITA margin (%) 19.00% 21.20% 17.30% 19.00%
Other income 63.6 47.8 (24.80%) 111.5 79.4 (28.80%)
Interest 39.5 32.9 (16.70%) 79.8 69.7 (12.70%)
Depreciation 123.3 139.2 12.90% 239.9 262.7 9.50%
Profit before tax 1,230 1,690 37.30% 2,064 2,790 35.20%
Minority Interest 4 (11) 3 (7)
Extraordinary Items 0 0 0 0
Tax 156.1 287.1 83.90% 282.9 477.4 68.80%
Profit after tax/(loss) 1,074 1,402 30.60% 1,781 2,313 29.80%
Net profit margin (%) 15.40% 16.40% 13.60% 14.40%
No. of shares (m) 866 866 866 866
Diluted earnings per share (Rs)* 5.1
Price to earnings ratio (x)* 30.5
                                                        * On a trailing 12-months basis




What has driven growth in 1QFY10?

- Sales for the company increased on the back of strong volume growth across key categories.

- The company rolled out several new products during the quarter like Dabur Uveda range of Ayurvedic skin care products, Babool Mint Fresh Gel and Fem Herbal Bleach, Dabur Amla Flower Magic Hair Oil, Vatika enriched Almond Hair Oil and Dabur Total Protect Ayurvedic health shampoo which helped grow sales.

- The company’s overseas business performed strongly with a sales growth for 2QFY10 recorded at 27.5% YoY. Of the overseas markets, Nepal was the strongest performer with sales growth of 41.4% YoY. 36.8% YoY growth in sales was recorded in GCC while sales in Egypt grew by 35.3% YoY.

- Net profit for the quarter grew by 29% YoY due to higher tax expense which grew by 84%. This is due to some of the company’s manufacturing hubs coming out of the tax exemption period.


Related Articles

Nestle India (BOM:500790)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki